Recent Advances in Hematology: Targeted Therapy, Immunotherapy, Gene Editing, and Novel Anticoagulants

1. Targeted Therapies

  • CML: Imatinib, dasatinib, nilotinib, bosutinib, ponatinib (BCR-ABL1 TKIs).
  • CLL: Ibrutinib, acalabrutinib, zanubrutinib (BTK inhibitors); venetoclax (BCL-2).
  • AML: Midostaurin, gilteritinib (FLT3); ivosidenib (IDH1); enasidenib (IDH2).

2. Immunotherapy

  • CAR T-cell: Tisagenlecleucel, axicabtagene ciloleucel, lisocabtagene maraleucel (CD19+ B-ALL, DLBCL); idecabtagene vicleucel, ciltacabtagene autoleucel (BCMA+ myeloma).
  • Bispecifics: Blinatumomab (CD3×CD19), teclistamab (CD3×BCMA), mosunetuzumab (CD3×CD20).
  • Checkpoint inhibitors: Pembrolizumab (PMBCL, cHL).

3. Stem Cell Transplant Innovations

  • Reduced-intensity conditioning (RIC) expands eligibility.
  • Haploidentical donors plus post-transplant cyclophosphamide (PTCy) broadens donor pool.
  • Cord blood expansion (omidubicel) accelerates engraftment.

4. Gene Therapy and Editing

  • Sickle cell and β-thalassemia: Exagamglogene autotemcel (Casgevy, CRISPR-Cas9 BCL11A editing); lovotibeglogene autotemcel (Lyfgenia, lentiviral βA-T87Q-globin).
  • Hemophilia A/B: AAV-mediated factor VIII/IX gene transfer (valoctocogene roxaparvovec, etranacogene dezaparvovec).

5. Novel Oral Anticoagulants (DOACs)

  • Apixaban, rivaroxaban, edoxaban, dabigatran — predictable PK, no routine monitoring, lower intracranial bleed vs. warfarin.
  • Indications: AFib, VTE treatment/prevention, post-orthopedic surgery.

6. Hematopoietic Growth Factors

  • Erythropoiesis-stimulating agents (epoetin, darbepoetin) for CKD/chemo anemia.
  • G-CSF/GM-CSF (filgrastim, sargramostim) for neutropenia.
  • Thrombopoietin receptor agonists (romiplostim, eltrombopag, avatrombopag) for ITP, chemotherapy-induced thrombocytopenia.

These advances collectively shift hematology toward precision, curative-intent, and quality-of-life-focused care.

Blood Disorders - Related Articles